Rivaroxaban for the treatment of venous thromboembolism
N Kucher, D Aujesky, JH Beer… - Thrombosis and …, 2016 - thieme-connect.com
We investigated three-month clinical outcomes in patients with venous thromboembolism
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …
(VTE) treated with rivaroxaban or conventional anticoagulation in routine clinical practice …
Rivaroxaban for the treatment of venous thromboembolism. A “real-life” perspective in 103 patients
L Jara-Palomares, R Sanchez-Oro-Gomez… - Thrombosis research, 2014 - Elsevier
Introduction Randomized clinical trials have demonstrated non-inferiority of rivaroxaban
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …
compared with vitamin K antagonists (VKAs) in the treatment of venous thromboembolism …
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism
CI Coleman, TJ Bunz… - Thrombosis and …, 2017 - thieme-connect.com
The efficacy and safety or rivaroxaban versus enoxaparin/vitamin K antagonist for treatment
and prevention recurrence of venous thromboembolism (VTE) was demonstrated in the …
and prevention recurrence of venous thromboembolism (VTE) was demonstrated in the …
Oral rivaroxaban for symptomatic venous thromboembolism
Einstein Investigators - New England Journal of Medicine, 2010 - Mass Medical Soc
Background Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …
regimen for treating acute deep-vein thrombosis (DVT) and for continued treatment, without …
Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study
Background Deep vein thrombosis (DVT) and pulmonary embolism are collectively known
as venous thromboembolism (VTE), which is a common vascular disease and a major cause …
as venous thromboembolism (VTE), which is a common vascular disease and a major cause …
Effectiveness and safety of rivaroxaban versus warfarin in patients with unprovoked venous thromboembolism: A propensity-score weighted administrative claims …
CI Coleman, WF Peacock, TJ Bunz… - Thrombosis research, 2018 - Elsevier
Background In phase III trials, rivaroxaban demonstrated non-inferiority over
enoxaparin/warfarin to prevent recurrent venous thromboembolism (VTE), with a reduction …
enoxaparin/warfarin to prevent recurrent venous thromboembolism (VTE), with a reduction …
Comparative safety and effectiveness of rivaroxaban versus VKAs in patients with venous thromboembolism
C Sindet-Pedersen, JL Pallisgaard… - Thrombosis and …, 2017 - thieme-connect.com
The approval of rivaroxaban has changed the landscape of treatment of venous
thromboembolism (VTE). Little is known about the effect of rivaroxaban compared with …
thromboembolism (VTE). Little is known about the effect of rivaroxaban compared with …
Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study
C Sindet-Pedersen, L Staerk… - European Heart …, 2018 - academic.oup.com
Aims To investigate the risk of all-cause mortality, recurrent venous thromboembolism (VTE),
and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban …
and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban …
Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta‐Analysis of Real‐World …
Background. Rivaroxaban and apixaban are the most widely used nonvitamin K oral
anticoagulants (NOACs) in patients with venous thromboembolism (VTE). This meta …
anticoagulants (NOACs) in patients with venous thromboembolism (VTE). This meta …
[HTML][HTML] Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies
HR Buller - Blood, 2012 - Elsevier
Abstract Abstract 20 Harry R. Büller, MD, PhD on behalf of the EINSTEIN Investigators.
Background The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose …
Background The EINSTEIN DVT and EINSTEIN PE studies showed that a fixed-dose …
相关搜索
- venous thromboembolism effectiveness of rivaroxaban
- venous thromboembolism apixaban in patients
- venous thromboembolism warfarin for treatment
- thromboembolism patients safety of rivaroxaban
- warfarin for treatment safety of rivaroxaban
- venous thromboembolism prevention of recurrence
- venous thromboembolism meta analysis
- venous thromboembolism effectiveness and safety
- venous thromboembolism anticoagulants rivaroxaban
- venous thromboembolism rivaroxaban and apixaban
- venous thromboembolism safety of rivaroxaban
- venous thromboembolism treatment and prevention
- venous thromboembolism vkas in patients
- treatment and prevention safety of rivaroxaban